Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas. [electronic resource]
Producer: 20161102Description: 1713-9 p. digitalISSN:- 1556-1380
- Adenocarcinoma -- drug therapy
- Adenocarcinoma of Lung
- Adult
- Aged
- Aged, 80 and over
- Class I Phosphatidylinositol 3-Kinases
- Drug Resistance, Neoplasm
- ErbB Receptors -- antagonists & inhibitors
- Female
- Humans
- Lung Neoplasms -- drug therapy
- Male
- Middle Aged
- Mutation
- Phosphatidylinositol 3-Kinases -- genetics
- Prognosis
- Protein Kinase Inhibitors -- therapeutic use
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.